Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.biofilgroup.net | |
Market Cap | 80.56 Cr. | |
Enterprise Value(EV) | 80.90 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.35 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 143.08 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.44 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 10.50 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 4.71 | Calculated using Price: 49.50 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.63 Cr. | 16,273,800 Shares |
FaceValue | 10 | |
Company Profile | ||
Biofil Chemicals & Pharmaceuticals established in 1985, is part of Cyano Group of Industries. The company is into manufacturing of drugs in area of anti-bacterial, analgesics/antipyretics, anti-malarial, anti-psychotics, anti asthmatic/bronchodilators, diuretics, tranquilizer/hypnotics, anti inflammatory, analgesic/antipyretics, anti inflammatory steroids and eye/ear drops |
1 Day |
|
+0.90% |
1 Week |
|
-4.72% |
1 Month |
|
-6.92% |
3 Month |
|
-10.23% |
6 Month |
|
-6.92% |
1 Year |
|
-35.86% |
2 Year |
|
-45.34% |
5 Year |
|
+247.93% |
10 Year |
|
+1452.31% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 13.53 | 13.47 | 13.28 | 18.09 | 3.64 | 3.60 | 8.46 | 8.01 | 4.24 | |
Return on Capital Employed (%) | 12.09 | 12.97 | 14.04 | 21.86 | 5.13 | 5.06 | 10.12 | 12.18 | 6.23 | |
Return on Assets (%) | 3.68 | 4.14 | 4.13 | 7.81 | 2.05 | 1.99 | 3.63 | 3.28 | 2.69 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 8 | 8 | 11 | 13 | 13 | 14 | 15 | 16 | 17 | 17 | |
Non Curr. Liab. | 0 | 0 | 0 | ||||||||
Curr. Liab. | 7 | 5 | 13 | 9 | 11 | 11 | 27 | 17 | 1 | 16 | |
Minority Int. | |||||||||||
Equity & Liab. | 15 | 14 | 24 | 22 | 24 | 24 | 42 | 33 | 19 | 33 | |
Non Curr. Assets | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 9 | 9 | |
Curr. Assets | 5 | 5 | 15 | 13 | 15 | 14 | 32 | 23 | 9 | 24 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 15 | 14 | 24 | 22 | 24 | 24 | 42 | 33 | 19 | 33 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 7 | 6 | 13 | 13 | 12 | 23 | 30 | 36 | 22 | 18 | |
Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
Total Income | 7 | 6 | 14 | 14 | 12 | 23 | 30 | 37 | 23 | 18 | |
Total Expenditure | -6 | -5 | -12 | -11 | -11 | -22 | -28 | -34 | -21 | -17 | |
PBIDT | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 2 | 1 | 1 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Taxation | 0 | 0 | 0 | -1 | 0 | 0 | 0 | -1 | 0 | 0 | |
Exceptional Items | |||||||||||
PAT | 1 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | |
Adjusted EPS | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | |
Cash Fr. Inv. | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | |
Cash Fr. Finan. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | 0 | |
Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fri, 06 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations 2018 for the quarter ended on 31st December 2022 |
Wed, 28 Dec 2022
Closure of Trading Window This is with reference to the BSE Circular Ref No.LIST/COMP/01/2019-20 and NSE Circular Ref No.NSE/CML/2019/11 dated 02.04.2019 we wish to inform you that in terms of Companys Code of Conduct to regulate monitor and report trading in Companys Securities by Insiders framed under SEBI (Prohibition of Insider Trading) Regulations 2015 the trading window for dealing in the Securities of Company will remain closed for all Designated Persons their immediate relatives and connected persons (as defined in the Code) w.e.f. January 01 2023 for the purpose of consideration of Un-Audited Financial Results for the quarter and nine months ended on December 31 2022. |
Sat, 24 Dec 2022
Disclosure Under Regulation 30(5)Of The SEBI(LODR) Regulation 2015 Pursuant to requirement of Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that the following persons are authorized for the purpose of determining the materiality of event or information and have been authorized for making the disclosure to the Stock exchange as and when required |
Thu, 02 Feb 2023 |
|
|
|
|
|